|
Repurposing H1 and H2 antihistamines for the treatment of erythropoietic protoporphyria
Invention Summary:
Erythropoietic protoporphyria (EPP) is a severe genetic disorder caused by defects in heme biosynthesis, leading to the accumulation of protoporphyrin IX (PP-IX) in the liver. This accumulation results in cholestasis and, in the most severe cases, end-stage liver failure, necessitating liver transplantation or leading to...
Published: 2/4/2025
|
Inventor(s): Bishr Omary, Ning Kuo
Keywords(s):
Category(s): Technology Classifications > Therapeutics, Technology Classifications > Rare Disease
|
|
PKC412 restores functionality of the keratin cytoskeleton in the skin disorder epidermolysis bullosa simplex
Invention Summary:
Epidermolysis bullosa simplex (EBS) is a highly penetrant genetic condition that causes fragility of skin keratinocytes resulting in fluid-filled skin blisters that erode upon scratching or minor pressure on the skin. There is no good cure for EBS, and treatment typically involves preventive and/or supportive care...
Published: 10/21/2024
|
Inventor(s): Bishr Omary, Thomas Magin, Jacques Roberge, Katrin Rietscher, Pei Li
Keywords(s): Dermatology
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Rare Disease
|
|
Use of Retinoids in Congenital Erythropoietic Porphyria
Invention Summary:
Congenital erythropoietic porphyria (CEP) is an unaddressed orphan disease caused by a rare genetic disorder leading to accumulation of uro/coproporphyrin-I (uro-I) in tissues due to inhibition of the enzyme uroporphyrinogen-III synthase. Clinical manifestations of CEP include bone fragility, severe photosensitivity, and photo-mutilation....
Published: 8/28/2024
|
Inventor(s): Bishr Omary, Jordan Shavit
Keywords(s): Small molecules
Category(s): Technology Classifications > Therapeutics, Technology Classifications > Healthcare & Life Sciences
|
